



The first and only oral vasopressin antagonist that increases free water clearance and serum sodium concentrations

**EXPLORE THE DATA**

**IMPORTANT SAFETY INFORMATION and INDICATION**  
SAMSICA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., > 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, FULL PRESCRIBING INFORMATION including Boxed WARNING

THE JOURNAL OF  
CLINICAL ENDOCRINOLOGY  
& METABOLISM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH



**This version published online on June 16, 2010**

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2010-1025

Submitted on May 4, 2010

Accepted on May 24, 2010

## Central Precocious Puberty in Children Living in Spain: Incidence, Prevalence, and Influence of Adoption and Immigration

Leandro Soriano-Guillén, Raquel Corripio, José Ignacio Labarta, Ramón Cañete, Lidia Castro-Feijóo, Rafael Espino, and Jesús Argente\*

Pediatric Endocrinology Unit (L.S.-G.), Institute of Biomedical Research-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, E-28049 Madrid, Spain; Pediatric Endocrinology Unit (R.C.). Corporación Parc Taulí Hospital de Sabadell, Universidad Autónoma de Barcelona, E-08193 Barcelona, Spain; Pediatric Endocrinology Unit (J.I.L.), Hospital Universitario Miguel Servet, Zaragoza, Universidad de Zaragoza, E-50009 Zaragoza, Spain; Pediatric Endocrinology Unit (R.C.), Hospital Universitario Reina Sofía, Córdoba, Universidad de Córdoba, E-14071 Córdoba, Spain; Pediatric Endocrinology, Growth, and Adolescence Unit (L.C.-F.). Hospital Clínico Universitario Santiago de Compostela, Universidad de Santiago de Compostela, E-15705 Santiago de Compostela, Spain; Pediatric Endocrinology Unit (R.E.), Hospital Valme, E-41014 Sevilla, Spain; Department of Pediatrics (J.A.), Universidad Autónoma de Madrid, Department of Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús and Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, E-28009 Madrid, Spain

\* To whom correspondence should be addressed. E-mail: [argentefen@terra.es](mailto:argentefen@terra.es).

**Context:** No epidemiological data are available on central precocious puberty (CPP) in the general population or in adopted or immigrant children in Spain.

**Objective:** We aimed to study the incidence and prevalence of CPP, assess the risk of developing this disorder among adopted and immigrant children, and analyze the predictive variables of CPP associated with intracranial pathology.

**Design, Settings, and Patients:** An observational study of children diagnosed with CPP in Spain was carried out between January 2008 and January 2010. A computer program was designed to process clinical and biological data and information on 250 patients treated in 34 pediatric endocrinology units throughout the country.

**Results:** Of the patients registered, 226 were girls and 24 were boys. The global incidence rate of CPP was 5.66 cases per million person-years at risk, with an annual incidence ranging between 0.02 and 1.07 new cases per 100,000. The relative risk of CPP in domestic and internationally adopted children compared with those born in Spain was 27.82 (19.99–38.77), whereas the relative risk among immigrants was 1.55 (0.97–2.38). A logistic regression model developed for the study showed that the combined effect of four variables had a significant influence over the presence of organic disease: being male, having been adopted, age at diagnosis, and estimation of adult height.

**Conclusions:** CPP is a rare disease whose risk markedly increases with both national and international adoption but is not influenced by immigration. These results suggest a psychological influence on CPP.

### This Article

- ✦ [Author Manuscript \(PDF\)](#)
- ✦ [Submit a related Letter to the Editor](#)
- ✦ [Alert me when this article is cited](#)
- ✦ [Alert me when eLetters are posted](#)
- ✦ [Alert me if a correction is posted](#)

### Services

- ✦ [Email this article to a friend](#)
- ✦ [Similar articles in this journal](#)
- ✦ [Similar articles in PubMed](#)
- ✦ [Alert me to new issues of the journal](#)
- ✦ [Download to citation manager](#)
- ✦ [Reprints, Permissions and Rights](#)

### Google Scholar

- ✦ [Articles by Soriano-Guillén, L.](#)
- ✦ [Articles by Argente, J.](#)

### PubMed

- ✦ [PubMed Citation](#)
- ✦ [Articles by Soriano-Guillén, L.](#)
- ✦ [Articles by Argente, J.](#)



The first and only oral vasopressin antagonist that increases free water clearance and serum sodium concentrations

**EXPLORE DATA**

**IMPORTANT SAFETY INFORMATION and INDICATION**  
SAMSICA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., > 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, FULL PRESCRIBING INFORMATION including Boxed WARNING